Cenicriviroc: Additional Ph IIb data

Additional data from the double-blind, international Phase IIb CENTAUR trial in 289 NASH patients with liver fibrosis and diabetes or metabolic syndrome showed that 16% of patients receiving once-daily 150 mg oral cenicriviroc for 2 years achieved a reduction in NAS of ≥2 points with no worsening in fibrosis, the primary endpoint, vs. 19% of patients receiving placebo (p=0.519). On a secondary endpoint, 8% of patients receiving cenicriviroc achieved complete resolution of steatohepatitis with no worsening of fibrosis vs. 6% of patients receiving placebo (p=0.494). Data were presented at the American Association for the Study of Liver Diseases meeting in Boston...